This white paper outlines the most common reasons the FDA has issued Form 483 Inspectional Observations since the beginning of FY 2016 through the present date and shows how an Enterprise Quality Management System (EQMS) can help pharmaceutical companies avoid running afoul of the FDA and other like-minded regulatory bodies.
The U.S. Food and Drug Administration (FDA) issues Form 483 Inspectional Observations or warning letters when communicating to a pharmaceutical company that its quality practices are not in compliance with regulatory standards. Most of these observations and warnings are due to some form of the following infractions:
Offered Free by: MasterControl Inc.
See All Resources from: MasterControl Inc.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.